research
blood
transfus
began
seventeenth
centuri
william
harvey
experi
circul
blood
richard
lower
pioneer
first
blood
transfus
anim
royal
societi
first
blood
transfus
anim
human
carri
jeanbaptist
deni
franc
blood
first
success
blood
transfus
perform
use
syring
british
obstetrician
jame
blundel
treat
postpartum
hemorrhag
subsequ
first
success
whole
blood
transfus
perform
treat
patient
hemophilia
samuel
lane
london
blood
transfus
avoid
late
nineteenth
centuri
sever
reaction
high
mortal
discoveri
three
blood
group
b
austrian
karl
landstein
blood
transfus
becam
safer
led
accept
modern
treatment
emerg
blood
loss
surgeri
wikipedia
first
blood
transfus
surgeri
perform
case
western
reserv
univers
cleveland
first
world
war
stimulu
rapid
develop
blood
bank
transfus
techniqu
world
first
blood
donor
servic
establish
british
red
cross
first
blood
bank
establish
leningrad
hospit
us
govern
establish
nationwid
program
blood
collect
highlight
transfus
medicin
histori
http
wwwaabborgtmpageshighlightsaspx
transfus
recogn
sourc
infect
descript
transfusiontransmit
tt
syphili
screen
syphili
blood
donor
institut
blood
bank
becam
common
paul
beeson
publish
classic
descript
highlight
transfus
medicin
histori
malari
parasit
may
first
microb
known
transmit
transfus
global
estim
million
unit
red
blood
cell
transfus
everi
year
transfus
blood
product
associ
sever
complic
due
immunolog
reaction
infect
immunolog
reaction
frequent
infect
includ
acut
hemolyt
anemia
often
due
human
error
cross
match
mismatch
blood
type
delay
hemolyt
reaction
h
day
usual
due
low
undetect
antirh
anti
kid
antibodi
febril
nonhemolyt
reaction
one
common
transfus
reaction
occur
due
releas
inflammatori
chemic
mediat
store
white
blood
cell
allerg
reaction
caus
ige
antiallergen
antibodi
donor
recipi
common
patient
hay
feverallergi
rare
anaphylact
reaction
caus
iga
antiplasma
protein
antibodi
extrem
rare
posttransfus
purpura
associ
presenc
antibodi
direct
donor
recipi
platelet
human
platelet
antigen
transfusionassoci
acut
lung
injuri
similar
acut
respiratori
distress
syndrom
ard
within
h
transfus
relat
donor
antibodi
interact
recipi
tissu
antigen
releas
inflammatori
cytokin
result
capillari
leakag
transfusionassoci
graft
versu
host
diseas
occur
immunodefici
patient
whose
bodi
fail
elimin
donor
cell
blood
common
nonimmunolog
complic
transfusionrel
circulatori
overload
within
h
acut
respiratori
distress
sign
heart
failur
blood
product
transfus
caus
infecti
complic
three
mechan
transfus
microb
present
asymptomat
donor
blood
mainli
virus
b
contamin
store
blood
product
primarili
bacteria
platelet
c
transfusionrel
immunosuppress
predispos
postop
infect
other
risk
infect
increas
amount
red
blood
cell
unit
blood
product
transfus
patient
requir
chronic
blood
product
vulner
despit
remark
progress
made
blood
blood
product
safeti
achiev
last
year
sinc
identif
human
immunodefici
viru
hiv
hepat
c
viru
hcv
concern
still
abound
risk
transmiss
emerg
infecti
agent
microb
transmit
transfus
certain
attribut
consid
necessari
presenc
agent
blood
donor
asymptomat
phase
agent
survivalpersist
blood
processingstorag
agent
must
recogn
respons
clinic
illnessoutcom
proport
infect
recipi
group
expert
member
aabb
transfus
transmit
diseas
committe
identifi
infecti
diseas
agent
capabl
transmit
blood
transfus
howev
list
even
larger
keep
expand
rate
emerg
new
agent
new
virus
discov
everi
year
anim
origin
infect
human
infecti
agent
classifi
priorit
risk
level
base
combin
scientificepidemiolog
assess
public
percept
regulatori
concern
red
orang
yellow
white
categori
list
includ
wellacknowledg
transfusiontransmit
hcv
hepat
b
viru
hbv
treponema
pallidum
red
agent
low
high
scientif
evid
blood
safeti
risk
potenti
sever
clinic
outcom
includ
human
variant
creutzfeldtjakob
diseas
vcjd
dengu
virus
denv
babseia
speci
vcjd
low
low
risk
transmiss
north
america
na
higher
risk
transmiss
unit
kingdom
uk
first
describ
denv
low
low
almost
absent
risk
transmiss
na
moder
risk
endem
countri
howev
moder
risk
transmiss
usa
low
risk
canada
europ
countri
parasit
endem
orang
categori
agent
suffici
scientificepidemiolog
evid
blood
transmiss
risk
may
support
higher
prioriti
futur
includ
chikungunya
viru
chikv
potenti
risk
proven
transfus
transmit
st
loui
enceph
viru
slev
potenti
risk
proven
leishmania
speci
low
risk
blood
transmiss
proven
possibl
case
mainli
endem
area
plasmodium
speci
well
document
blood
transmiss
low
nonendem
countri
high
hyperendem
region
trypanosoma
cruzi
chaga
diseas
well
document
blood
transmit
low
usa
europ
moder
south
central
america
yellow
categori
agent
low
absent
risk
blood
transmiss
public
regulatori
concern
agent
includ
chronic
wast
diseas
cwd
prion
agent
never
detect
human
donat
blood
human
transmit
transfus
africa
possibl
usa
proven
result
clinic
diseas
hiv
variant
potenti
blood
transmiss
never
proven
human
parvoviru
proven
transmit
blood
four
document
case
low
risk
except
hemophilia
condit
requir
recurr
chronic
transfus
immunosuppress
avian
influenza
viru
subtyp
unlik
blood
transmit
high
profil
possibl
pandem
spread
simian
foami
viru
transmit
blood
transfus
nonhuman
primat
never
demonstr
human
theoret
possibl
borrelia
burgdorferi
lyme
diseas
agent
potenti
possibl
proven
case
transfus
transmit
hepat
viru
hav
rare
transmit
transfus
neonat
intens
care
unit
white
categori
agent
repres
watch
list
subject
modif
chang
accord
circumst
agent
includ
hepat
e
viru
hev
document
blood
transfus
transmit
endem
region
industri
countri
mainli
zoonot
subtyp
anaplasma
phagocytocytophilum
document
transfus
transmit
usa
case
potenti
greater
blood
transmiss
due
high
seropreval
region
usa
unknown
period
bacteremia
surviv
refriger
store
blood
shown
anim
model
transfus
transmitt
sinc
aabb
group
public
list
agent
updat
six
new
addit
includ
yellow
fever
virus
miscellan
arbovirus
xmrv
human
parvovirus
bocavirus
measl
viru
merscov
tabl
list
microorgan
recommend
screen
donat
blood
china
recent
data
blood
donor
screen
hiv
hbv
hcv
syphili
southwest
region
show
decreas
trend
time
period
combin
four
agent
slightli
lower
region
syphili
preval
especi
femal
farmer
rural
region
sinc
establish
blood
servic
china
experienc
sever
catastroph
transfusiontransmit
diseas
past
sinc
undergon
transform
chang
donor
screen
donor
test
donor
select
voluntari
donat
fix
group
donat
blood
undergo
two
round
test
differ
equip
reagent
differ
personnel
sinc
nucleic
acid
test
nat
establish
sever
blood
center
govern
invest
nationwid
expans
nat
howev
china
blood
servic
screen
agent
region
endem
transmit
transfus
nationwid
distribut
nine
potenti
agent
could
target
recent
review
infecti
agent
includ
plasmodium
spp
human
parvoviru
denv
brucella
spp
sever
fever
thrombocytopenia
syndrom
viru
sftsv
leishmania
spp
htlv
coxiella
burnetii
q
fever
despit
malaria
endem
region
china
previou
report
least
case
transmit
transfus
preval
malari
parasit
blood
donor
unknown
screen
blood
perform
denv
also
endem
part
china
blood
donor
endem
area
guangdong
provinc
igm
preval
rate
one
donor
rna
load
copiesml
brucellosi
endem
farm
commun
north
china
preval
rate
among
blood
donor
endem
area
xinjiang
provinc
report
brucella
dna
detect
sftsv
tickborn
bunyaviru
first
describ
china
concentr
mountain
rural
area
centraleastern
china
episod
outbreak
spring
autumn
transfusiontransmit
case
describ
seropreval
rate
blood
donor
endem
area
nonendem
area
two
lowgrad
suspect
virem
sampl
detect
rna
test
hev
found
worldwid
mani
case
transmit
blood
transfus
world
screen
blood
donor
six
urban
blood
center
china
report
show
preval
antihev
igg
antihev
igm
hev
rna
among
donat
htlv
preval
china
low
latest
nationwid
surveil
blood
donor
report
rate
leishmania
spp
transmit
transfus
parasit
surviv
human
red
blood
cell
rbc
storag
condit
day
case
kalaazar
report
yearli
china
mainli
xinjiang
provinc
western
provinc
howev
surveil
studi
blood
donor
document
transfusiontransmit
case
china
document
transmit
blood
transfus
caus
rbc
aplasia
immunosuppress
among
chines
blood
donor
dna
detect
tibetan
popul
howev
dna
detect
plasma
pool
use
manufactur
intraven
immunoglobulin
factor
viii
fibrinogen
etc
viral
load
geqml
higher
recommend
us
fda
geqml
c
burnetii
dna
detect
blood
donat
seroposit
donor
larg
outbreak
qfever
netherland
blood
donor
screen
initi
china
qfever
mainli
endem
tibet
inner
mongolia
western
china
threat
bloodborn
pathogen
disproportion
high
subsaharan
africa
variat
among
countri
eritrea
blood
donor
screen
least
donat
blood
posit
one
acknowledg
transfusiontransmitt
infect
tti
hbv
hiv
hcv
syphili
multipl
infect
seropreval
hbv
hcv
hiv
syphili
coinfect
respect
rate
rel
low
compar
countri
subsaharan
africa
ethiopia
similar
data
collect
blood
donor
overal
seropreval
tti
preval
hbv
hiv
hcv
syphili
respect
higher
preval
tti
report
eastern
ethiopia
major
due
hbv
western
kenya
seropreval
four
tti
voluntari
blood
donor
even
higher
distribut
among
hiv
hbv
hcv
syphili
respect
prospect
screen
donor
nigeria
show
infect
least
one
four
tti
overal
preval
hbv
hcv
syphili
hiv
respect
howev
rate
tti
declin
significantli
year
remark
declin
hiv
seropreval
four
main
tti
among
blood
donor
report
differ
report
recent
review
studi
found
west
african
countri
highest
seropreval
tti
countri
especi
hbv
hcv
hiv
preval
demonstr
declin
pattern
throughout
year
blood
transfusiontransmittedassoci
hiv
infect
nigeria
previous
report
respons
children
infect
western
cape
provinc
south
africa
blood
suppli
appear
except
safe
introduct
nat
sinc
preval
rate
main
tti
blood
donor
appear
lower
middl
eastern
countri
africa
asian
countri
declin
rate
iran
overal
seropreval
rate
hbv
hcv
hiv
respect
similarli
low
rate
tti
report
among
blood
donor
jordan
data
egypt
indic
preval
hiv
syphili
extrem
low
hcv
hbv
respect
still
pose
signific
risk
blood
transmiss
recent
preval
data
saudi
arabia
among
blood
donor
use
serolog
test
nat
rel
small
sampl
found
hbv
sag
hcv
hiv
htlv
hbv
cab
addit
detect
nat
among
blood
donor
pakistan
tti
detect
multipl
infect
rapid
immunochromatograph
techniqu
overal
frequenc
hcv
syphili
hbv
malaria
hiv
respect
preval
rate
tti
appear
lower
india
overal
posit
tti
among
donor
kolkata
cumul
seropreval
darjeel
hiv
hbv
hcv
syphili
respect
anoth
studi
india
report
preval
tti
higher
replac
donor
voluntari
donor
overal
decreas
preval
infect
donat
blood
decreas
thailand
compar
rate
hiv
hbv
hcv
syphili
respect
seropreval
data
usual
tti
blood
donor
south
american
countri
incomplet
partial
present
countri
within
last
year
brazil
nat
introduc
hiv
hcv
preval
two
virus
recent
estim
per
donat
respect
argentina
introduc
nat
screen
blood
bank
year
report
posit
donor
hiv
hcv
hbv
may
repres
intermedi
risk
comparison
african
countri
develop
nation
limit
data
colombia
donor
year
note
preval
rate
chaga
diseas
hbv
hcv
hiv
syphili
total
preval
highincom
industri
countri
low
rate
usual
tti
blood
donor
recent
updat
seropreval
present
data
million
donat
collect
usa
repres
blood
suppli
surveillanceposit
rate
per
donat
hbv
hcv
hiv
htlv
dutch
experi
recent
updat
preval
tti
among
blood
donor
lower
gener
popul
new
donor
higher
rate
tti
compar
repeat
donor
preval
rate
tti
per
donor
hbv
hcv
hiv
htlv
syphili
preval
tti
dutch
donor
popul
typic
lower
industri
countri
rate
vari
hbv
hcv
hiv
htlv
per
donor
risk
tti
variabl
differ
region
world
depend
sever
factor
preval
tti
donor
popul
type
donor
routin
use
voluntari
replac
paid
screen
deferr
donor
method
test
blood
donat
serolog
antigen
detect
nat
pathogen
reduct
techniqu
treat
donat
blood
gener
industri
countri
use
multipl
method
includ
nat
plu
low
preval
major
tti
lowest
risk
tti
poor
lowincom
countri
especi
africa
higher
preval
tti
less
depend
voluntari
donat
lack
facil
nat
greatest
risk
tti
wherea
middleincom
countri
brazil
china
etc
intermedi
risk
usual
tti
see
tabl
compar
rate
tti
cytomegaloviru
cmv
latent
infect
common
adult
popul
industri
countri
develop
nation
transmit
blood
resid
leukocyt
person
infect
indefinit
transmiss
cmv
pose
signific
health
hazard
healthi
adult
older
child
result
sever
diseas
immunocompromis
cmvseroneg
patient
ie
stem
cell
transplant
prematur
neonat
measur
reduc
ttcmv
highrisk
group
includ
deplet
cellular
blood
product
leukoreduct
select
cmvneg
donat
studi
indic
newli
posit
cmvigg
donor
pose
highest
risk
transmit
cmv
blood
contain
highest
level
cmv
dna
howev
scientif
evid
accord
recent
review
leukoreduct
singl
strategi
reduc
risk
ttcmv
infect
highrisk
patient
transfusiontransmiss
hbv
extrem
low
develop
middleincom
countri
screen
blood
hbsag
nat
residu
risk
still
remain
blood
donor
extrem
low
viral
dna
blood
occult
hbv
infect
intermitt
shed
liver
detect
even
highli
sensit
nat
model
estim
residu
transmiss
risk
occult
hbv
donat
hbsag
nat
nonreact
despit
nat
test
hbv
case
tthbv
infect
occur
annual
occult
recent
infect
window
period
japan
individu
nat
reveal
donat
low
antihbc
antihb
titer
virem
sinc
japanes
blood
servic
elect
discard
unit
low
antihbc
antihb
account
total
donat
studi
australia
without
univers
antihbc
test
estim
occult
hbv
residu
risk
unit
transfus
repres
total
hbv
risk
decreas
individu
nat
identifi
repeat
blood
donor
occult
infect
data
brazil
indic
presenc
high
antihb
titer
miuml
preclud
presenc
hbv
dna
donor
blood
recent
studi
report
slovenian
blood
donor
occult
hbv
infect
infect
recipi
extrem
low
viral
load
studi
suggest
minim
infecti
dose
revis
copi
iu
hbv
dna
prevent
could
achiev
univers
antihbc
screen
perform
center
highli
sensit
nat
abl
detect
copi
iuml
pathogen
reduct
method
hepat
e
viru
hev
worldwid
distribut
million
case
year
tropicalsubtrop
countri
caus
death
year
endem
epidem
diseas
countri
asia
africa
central
america
etc
caus
genotyp
rout
transmiss
europ
north
america
part
asia
ie
japan
genotyp
zoonos
present
mani
anim
especi
domest
pig
caus
sporad
infect
consumpt
raw
undercook
pork
also
blood
transfus
hev
virem
blood
donor
usual
asymptomat
normal
transaminas
donor
screen
interview
benefici
moreov
asymptomat
hevviremia
present
day
although
infect
hev
caus
asymptomat
mild
hepat
fulmin
diseas
seen
pregnanc
patient
preexist
cirrhosi
chronic
hepat
progress
cirrhosi
occur
immunosuppress
also
concern
organ
transplant
recipi
patient
hematolog
malign
commonli
receiv
blood
blood
product
transfus
immunocompromis
patient
develop
chronic
hev
infect
hev
genotyp
transmiss
blood
transfus
first
describ
endem
area
sinc
case
report
industri
countri
genotyp
case
report
europ
franc
germani
spain
uk
australia
canada
japan
tthev
occur
transfus
rbc
platelet
concentr
fresh
frozen
plasma
pool
granulocyt
present
case
tthev
japan
least
case
transfus
hev
blood
product
result
hev
infect
univers
screen
blood
product
hev
rna
controversi
topic
europ
polici
vari
among
countri
england
blood
donat
retrospect
screen
detect
hev
rna
follow
recipi
show
evid
hev
infect
preval
hev
viremia
blood
donor
vari
netherland
usa
risk
virem
blood
lead
infect
estim
risk
develop
clinic
infect
recipi
virem
blood
product
may
depend
presenc
antibodi
viral
load
volum
transfus
blood
minim
infect
dose
unknown
low
viral
load
iuml
associ
hev
infect
lowest
inoculum
known
lead
infect
recipi
iu
hev
rna
screen
blood
donat
routin
perform
ireland
uk
netherland
select
screen
use
highrisk
patient
perform
blood
center
germani
franc
switzerland
arbovirus
worldwid
distribut
region
variat
depend
speci
signific
risk
transmiss
transfus
short
period
asymptomat
viremia
especi
peak
season
high
incid
infect
howev
often
difficult
prove
ttarboviru
infect
vectorborn
transmiss
endem
region
although
transmiss
blood
product
proven
arbovirus
major
concern
sinc
zika
viru
epidem
america
year
ago
infect
zika
viru
commonli
asymptomat
virem
donor
could
easili
miss
moreov
ttzika
pregnant
women
could
result
sever
neurolog
fetal
abnorm
although
colorado
tick
fever
viru
first
arboviru
report
transmit
blood
transfus
concern
ttarbovirus
becam
blood
safeti
issu
west
nile
viru
outbreak
usa
west
nile
viru
caus
asymptomat
infect
major
patient
sever
neurolog
diseas
occur
elderli
immunocompromis
subject
us
outbreak
blood
donor
link
infect
recipi
donor
neg
west
nilespecif
igm
antibodi
time
donat
estim
risk
ttwest
nile
viru
epidem
period
per
donat
sinc
yearli
season
outbreak
summer
fall
occur
north
america
decreas
intens
nation
screen
nat
institut
initi
minipool
year
switch
individu
donat
onethird
rnaposit
donat
miss
minipool
screen
due
lowlevel
viremia
caus
infect
estim
west
nile
viru
screen
usa
per
qualityadjust
life
year
arbovirus
shown
transmit
transfus
dengu
viru
denv
tickborn
enceph
viru
despit
high
incid
dengu
fever
mani
tropic
countri
annual
least
million
global
denv
rare
report
transmit
transfus
welldocu
cluster
ttdenv
infect
howev
retrospect
analysi
larg
epidem
brazil
abl
identifi
cluster
ttdenv
viremia
confirm
donat
epidem
denv
rnaposit
unit
transfus
recipi
howev
infect
occur
suscept
recipi
analysi
reveal
signific
associ
transmiss
viral
load
donor
recipi
evid
past
denv
infect
one
serotyp
chikungunya
viru
chikv
anoth
arboviru
result
clinic
ill
mimick
dengu
fever
result
sever
persist
arthralgia
arthriti
wide
distribut
tropic
larg
outbreak
america
caribbean
chikv
potenti
transmit
transfus
report
occur
chikv
infect
differ
denv
zika
viru
west
nile
viru
infect
infect
subject
symptomat
thu
lower
risk
asymptomat
virem
donat
risk
ttchikv
recent
assess
studi
thailand
mean
maxim
risk
virem
donat
epidem
period
estim
asymptomat
case
screen
donor
could
reduc
risk
rapid
pandem
spread
zika
viru
zikv
sinc
report
case
countri
territori
pose
greatest
risk
ttarboviru
virem
patient
infect
zikv
asymptomat
pose
threat
blood
suppli
outbreak
low
endem
spread
moreov
zikv
produc
sever
teratogen
effect
persist
whole
blood
month
four
possibl
case
ttzikv
report
brazil
zikv
outbreak
french
polynesia
blood
donor
posit
zikv
rna
subsequ
becam
symptomat
puerto
rico
introduc
nat
donat
blood
outbreak
zikv
rna
detect
similarli
nat
asymptomat
blood
donor
martiniqu
detect
zikv
rna
report
symptom
day
postdon
mainland
usa
local
acquir
case
mosquitoborn
zikv
infect
case
travelassoci
infect
report
consequ
sinc
august
donat
blood
usa
screen
zikv
rna
four
million
donat
screen
confirm
posit
individu
test
sampl
rate
donat
zikv
rna
level
rbc
vari
copiesml
detect
day
donat
plasma
detect
level
rang
copiesml
detect
day
donat
present
plan
nat
individu
donor
project
cost
million
annual
costeffect
blood
donat
screen
exceed
millionqualityadjust
lifeyear
qali
gain
time
high
cost
consid
appropri
clinic
medicin
current
us
strategi
individu
nat
zikv
recent
estim
cost
million
per
qali
screen
costeffect
high
mosquito
season
puerto
rico
ross
river
viru
rrv
arboviru
uniqu
australian
region
confirm
case
per
year
largest
outbreak
affect
peopl
australia
papua
new
guinea
solomon
island
recogn
risk
blood
suppli
like
chkv
rrv
caus
epidem
debilit
polyarthr
first
case
ttrrv
recent
describ
prompt
comprehens
risk
review
model
estim
risk
infect
donor
australia
predict
rrvinfect
blood
compon
issu
australia
period
parvoviru
infect
common
childhood
adulthood
seropreval
adolesc
adult
elderli
popul
mani
infect
subject
asymptomat
approxim
adult
children
outbreak
experi
mild
nonspecif
virallik
ill
thu
blood
may
donat
period
viremia
occur
week
exposur
last
day
import
pathogen
featur
bone
marrow
cell
tropism
especi
erythroid
progenitor
cell
increas
suscept
infect
differenti
transmiss
blood
product
feasibl
highlevel
viremia
regularli
occur
primari
infect
geqml
earli
phase
acut
infect
asymptomat
individu
frequent
found
blood
plasma
donat
commonli
transmit
pool
plasmaderiv
product
rbc
transmiss
via
plasmaderiv
product
occur
due
incomplet
clearanc
viru
blood
highlevel
viremia
acut
infect
resist
inactiv
procedur
use
prepar
bloodderiv
product
frequent
contamin
blood
plasma
donat
viru
dna
commonli
found
blood
product
multipl
donor
dna
detect
noninactiv
factor
viii
concentr
solventdetergentinactiv
ix
concentr
high
rate
dna
found
albumin
immunoglobulin
igg
prepar
factor
ix
pool
plasma
viral
load
geqml
sinc
transmiss
document
pooledplasma
product
less
iuml
dna
us
food
drug
administr
fda
impos
limit
geqml
dna
pool
plasma
cellular
blood
product
found
dna
rbc
transfus
associ
transmiss
primarili
highlevel
titer
iuml
howev
recent
report
japan
describ
persist
symptomat
infect
sever
thrombocytopenia
transmit
rbc
transfus
low
level
dna
iuml
fortun
patient
asymptomat
extent
clinic
diseas
transfus
transmiss
unknown
develop
diseas
influenc
presenc
hematolog
immunocompromis
disord
immun
statu
host
three
group
patient
particular
risk
seriou
diseas
infect
patient
chronic
hemolyt
disord
ie
thalassemia
major
sickl
cell
diseas
may
develop
transient
aplast
crisi
acut
infect
subject
combin
immunodefici
syndrom
develop
chronic
sever
anemia
bone
marrow
failur
patient
aid
develop
pure
red
cell
aplasia
fetal
abnorm
hydrop
fetali
occur
pregnant
women
method
use
ensur
safeti
plasmaderiv
product
includ
nat
plasma
minipool
individu
donat
multipl
step
viral
inactiv
remov
solventdeterg
superh
c
day
pasteur
nanofiltr
human
tlymphocyt
viru
retrovirus
chronic
infect
lymphocyt
transmit
transfus
small
proport
infect
individu
develop
clinic
diseas
mani
year
infect
five
ten
million
peopl
worldwid
africa
asia
caribbean
central
south
america
caus
debilit
spastic
myelopathi
htlvassoci
myelopathi
ham
adult
tcell
leukemialymphoma
atl
link
specif
diseas
entiti
limit
evid
affect
patient
may
develop
chronic
neurolog
problem
sensori
neuropathi
gait
disturb
bladder
dysfunct
motor
abnorm
mild
cognit
impair
chronic
lung
infect
dermat
primarili
occur
america
especi
amerindian
north
central
south
america
seroposit
pygmi
tribe
africa
viru
found
intraven
drug
abus
ivda
usa
southern
europ
primarili
shown
transmit
cellular
blood
product
asia
first
report
japan
caribbean
jamaica
north
america
rare
recogn
clinic
heart
transplant
recipi
franc
report
develop
earli
sign
ham
within
month
rapid
onset
like
relat
immunosuppress
two
case
report
atl
taiwan
patient
preexist
lymphoma
promyelocyt
leukemia
month
year
transmiss
current
mani
countri
test
antibodi
blood
donor
may
costeffect
high
preval
region
valu
highincom
lowpreval
countri
perform
univers
screen
controversi
debat
use
mathemat
costeffect
model
estim
test
new
blood
donor
htlv
cost
us
million
per
life
save
per
qualityadjust
lifeyear
gain
htlv
preval
per
preval
among
donor
per
cost
estim
us
million
per
life
save
per
qualityadjust
lifeyear
gain
mani
develop
countri
north
america
europ
australia
preval
less
per
million
univers
test
donor
appear
costeffect
yet
mani
low
middleincom
countri
much
higher
preval
antibodi
screen
perform
investig
filter
leukoreduct
pathogen
inactiv
method
compar
antibodi
screen
need
guid
nation
blood
collect
system
malari
protozoa
plasmodium
speci
appear
one
first
first
ttinfect
describ
major
four
plasmodium
speci
p
falciparum
p
vivax
p
malaria
p
oval
caus
ttmalaria
surviv
store
blood
even
frozen
longest
interv
exposur
transmiss
donat
estim
variabl
speci
year
p
falciparum
year
p
vivax
year
p
oval
year
p
malaria
ttmalaria
describ
endem
nonendem
countri
risk
ttmalaria
extrem
rare
industri
countri
still
major
challeng
resourcelimit
endem
countri
especi
subsaharan
africa
endem
countri
challeng
differenti
mosquitotransmit
ttmalaria
thu
transmiss
blood
transfus
frequent
unrecogn
underestim
recent
estim
indic
ttmalaria
case
per
million
nonendem
countri
case
per
million
endem
countri
donor
asymptomat
invari
semiimmun
low
level
parasitemia
miss
microscopi
transmiss
usual
whole
blood
pack
rbc
platelet
leukocyt
seldom
transmit
malaria
rbc
carri
recent
studi
within
past
year
demonstr
highrisk
ttmalaria
subsaharan
countri
median
preval
malaria
parasit
donat
blood
thick
smear
rang
kenya
nigeria
blood
donor
routin
test
malaria
malariaendem
countri
africa
includ
nigeria
pakistan
blood
smear
detect
malari
parasit
healthi
blood
donor
india
rate
rapid
diagnost
test
confirm
microscopi
although
nonendem
region
low
risk
ttmalaria
may
depend
proxim
endem
area
brazil
malaria
endem
amazon
river
basin
nonendem
extraamazon
region
ie
sao
paulo
state
howev
recent
studi
found
blood
donor
sao
paulo
posit
p
falciparum
p
vivax
recent
review
ttmalaria
nonendem
region
report
case
case
twentyfirst
centuri
two
recent
case
usa
fiftyfour
case
occur
american
contin
europ
mediterranean
area
india
southeast
asia
frequenc
differ
plasmodium
speci
p
falciparum
p
malaria
p
vivax
p
oval
p
knowlesi
mix
infect
p
falciparump
malaria
case
avian
speci
plasmodium
praecox
acquir
greec
fatal
outcom
occur
mainli
p
falciparum
rare
p
malaria
p
oval
fatal
attribut
malaria
prevent
measur
taken
blood
bank
avoid
ttmalaria
vari
wide
even
endem
region
countri
subsaharan
africa
malawi
sao
tome
princip
sierra
leon
screen
donat
blood
malaria
nonendem
countri
also
vari
countri
ie
usa
reli
predon
questionnair
potenti
screen
other
franc
uk
australia
use
antibodi
test
donor
consid
risk
preliminari
questionnair
screen
donat
blood
commonli
microscopi
blood
smear
rapid
diagnost
test
insensit
low
parasitemia
serolog
test
differenti
remot
current
infect
pcr
sensit
method
endem
resourc
countri
afford
method
widespread
use
pathogen
inactiv
method
use
combin
riboflavin
photosensit
uv
light
devic
mirasol
system
whole
blood
terumo
bct
lakewood
colorado
reduc
tt
malaria
without
damag
rbc
trypanosoma
cruzi
caus
chaga
diseas
widespread
throughout
rural
central
south
america
transmit
triatomin
bug
among
poor
live
substandard
hous
sever
cardiac
diseas
occur
chronic
infect
untreat
individu
ttchaga
diseas
cd
recogn
endem
area
mani
year
screen
blood
donor
institut
increas
migrat
latin
american
north
america
europ
ttcd
nonendem
countri
becom
concern
transmiss
cd
first
recogn
transmit
transfus
total
number
ttcd
estim
last
decad
ttcd
nonendem
countri
report
usa
n
spain
n
canada
n
australia
recent
switzerland
lowlevel
parasitemia
may
detect
sever
year
infect
asymptomat
individu
infect
parasit
surviv
blood
storag
even
freez
thaw
cellular
compon
blood
transmit
diseas
plasma
platelet
transfus
commonli
report
blood
product
associ
ttcd
probabl
higher
parasit
load
blood
product
prevent
ttchaga
includ
univers
select
donor
screen
questionnair
test
cruzi
antibodi
blood
donor
screen
usa
first
institut
chaga
diseas
decemb
least
infect
blood
donor
report
blood
bank
usa
cdc
chaga
diseas
surveil
state
weeklyjuli
donor
screen
chaga
diseas
nonendem
countri
includ
usa
canada
spain
uk
franc
switzerland
australia
babesiosi
zoonosi
caus
intraerythrocyt
parasit
babesia
spp
commonli
babesia
microti
usual
transmit
ixod
tick
resembl
malari
parasit
blood
smear
smaller
babesiosi
commonli
report
northeast
upper
midwestern
usa
europ
asia
pacif
includ
china
immunocompet
host
caus
mild
febril
ill
sever
diseas
signific
mortal
occur
immunocompromis
asplen
elderli
patient
ttbabesiosi
first
describ
usa
sinc
case
relat
transfus
describ
mortal
case
due
b
microti
least
case
babesia
duncani
recent
case
arkansa
secondari
babesia
divergen
multipl
rbc
transfus
describ
babesiosi
transmit
rbc
store
day
previou
frozen
rbc
rare
platelet
ttbabesiosi
endem
region
usa
increas
public
health
concern
screen
donor
b
microti
yet
mandat
routin
perform
babesia
seropreval
blood
donor
foci
new
york
found
along
coastal
connecticut
studi
screen
donat
blood
connecticut
massachusett
minnesota
wisconsin
serolog
pcr
b
microti
blood
sampl
confirm
posit
pcrposit
thu
screen
donat
blood
endem
region
usa
would
decreas
risk
tt
babesiosi
bacteri
infect
repres
foremost
infecti
risk
transfus
blood
product
commonli
due
bacteri
contamin
process
storag
blood
product
direct
effect
increas
recognit
indirect
effect
blood
transfus
associ
immunomodul
may
result
increas
risk
infect
leukocyt
reduct
blood
shown
reduc
risk
health
careassoci
infect
recent
review
health
careassoci
infect
rbc
transfus
restrict
transfus
compar
liber
transfus
strategi
reduc
overal
health
careassoci
infect
reduc
risk
seriou
infect
particularli
signific
patient
undergo
hip
knee
arthroplasti
well
sepsi
bacteri
contamin
blood
product
donor
skin
ie
propionibacterium
acn
staphylococci
environ
varieti
bacteria
yersinia
pseudomona
proteu
escherichia
coli
klebsiella
acinetobact
serratia
investig
found
yersinia
enterocolitica
common
organ
capabl
grow
multipli
low
temperatur
septic
transfus
reaction
commonli
platelet
rather
rbc
transfus
estim
risk
blood
product
contamin
bacteria
platelet
rbc
recent
evid
netherland
platelet
concentr
store
platelet
addit
solut
associ
fourfold
increas
risk
bacteri
infect
usa
approxim
million
unit
platelet
transfus
yearli
data
period
fatal
bacteri
contamin
platelet
product
record
per
year
per
million
platelet
transfus
sinc
appear
improv
fatal
record
bacteri
infect
staphylococcu
aureu
account
greatest
number
death
due
contamin
preced
year
bacteria
associ
fatal
includ
serratia
marcescen
klebsiella
pneumonia
morganella
morganii
pseudomona
fluorescen
acinetobact
speci
enterococcu
faecium
studi
activ
passiv
surveil
bacteri
contamin
platelet
report
cultur
platelet
sampl
studi
period
platelet
unit
transfus
bacteri
contamin
per
million
result
septic
transfus
reaction
highincom
countri
bacteri
contamin
platelet
though
common
transfusiontransmit
infect
rang
platelet
unit
rate
much
higher
resourcepoor
countri
africa
rate
bacteri
contamin
whole
blood
rbc
concentr
studi
subsahara
africa
averag
platelet
contamin
like
much
higher
prevent
bacteri
contamin
platelet
us
fda
recommend
enhanc
bacteri
test
pathogen
reductioninactiv
strategi
one
system
combin
ultraviolet
amotosalen
broadspectrum
pathogen
inactiv
approv
usa
europ
although
blood
suppli
safer
ever
still
major
concern
respect
transfusiontransmit
infect
especi
advent
emerg
infecti
agent
moreov
situat
resourcepoor
countri
especi
subsaharan
africa
still
remain
challeng
provid
safe
blood
suppli
compar
develop
nation
blood
use
declin
significantli
past
decad
usa
number
blood
unit
collect
distribut
american
red
cross
decreas
predict
decreas
rais
issu
crisi
us
blood
system
blood
essenti
medicin
replac
like
forese
futur
safer
blood
suppli
paramount
public
health
plan
prevent
multipl
infecti
agent
transmit
blood
transfus
expens
time
consum
cumbersom
mani
blood
donat
screen
measur
exceed
us
million
per
qualityadjust
lifeyear
gain
time
high
deem
appropri
clinic
medicin
key
safe
afford
blood
system
univers
appli
pathogenreduct
system
inactiv
virus
parasit
bacteria
prion
implement
resourcepoor
resourcerich
countri
alik
would
obviat
need
expens
screen
serolog
nat
other
sever
method
pathogen
reduct
alreadi
use
includ
mirasol
terumobct
lakewood
co
usa
use
combin
riboflavin
uvb
light
appli
rbc
platelet
reduc
ttvirus
includ
hiv
hcv
hbv
log
reduct
well
parasit
bacteria
intercept
ceru
corpor
concord
ca
usa
util
amotosalen
uva
light
shown
similar
properti
virus
bacteria
parasit
theraflex
macopharma
lill
franc
use
photochem
inactiv
differ
method
plasma
platelet
demonstr
efficaci
virus
bacteria
case
hiv
transmiss
occur
treatment
plasma
solventsdeterg
treatment
plasma
effect
wide
array
envelop
intracellular
virus
bacteria
protozoa
combin
filtrat
improv
efficaci
chemic
alkyl
agent
also
investig
larger
compar
trial
need
find
suitabl
techniqu
use
whole
blood
rbc
platelet
plasma
prevent
transfusiontransmit
infect
futur
